共 308 条
[1]
Jayson GC(2014)Front-line therapy of advanced ovarian cancer: new approaches Ovarian cancer Lancet 384 1376-1388
[2]
Kohn EC(2017)New treatments in ovarian cancer Ann Oncol 28 viii46-viii50-529
[3]
Kitchener HC(2017)Antiangiogenic therapy in oncology: current status and future directions Ann Oncol 28 viii57-viii60-917
[4]
Ledermann JA(2016)PARP inhibitors in ovarian cancer Lancet 388 518-921
[5]
Ledermann JA(2016)Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Ann Oncol 27 i40-i44-139
[6]
Pujade-Lauraine E(2005)Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 913-380
[7]
Jayson GC(2005)Regulation of homologous recombination in eukaryotes Nature 434 917-882
[8]
Kerbel R(2010)Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls Annu Rev Genet 44 113-414
[9]
Ellis LM(2017)Germline mutations in RAD51D confer susceptibility to ovarian cancer Gynecol Oncol 147 375-490
[10]
Harris AL(2011)Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene Nat Genet 43 879-1107